Tamoxifen for primary breast cancer prevention in BRCA heterozygotes.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  European Journal of Cancer

• Publication date

  2002-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0959-8049(02)00270-8PMID 12409059
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Variation in cancer risks, by mutation position, in BRCA2 mutation carriers.

  2001cited by this paper
• Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.

  2001cited by this paper
• Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

  2001cited by this paper
• Hereditary breast cancer.

  2001cited by this paper
• Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.

  2000cited by this paper
• Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2.

  1999cited by this paper
• Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.

  1999cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers.

  1998cited by this paper

• RETRACTED: Fe3O4 Nanoparticles for Complex Targeted Delivery and Boron Neutron Capture Therapy

  2019cites this paper
• BRCA1 and BRCA2 Testing in Inherited Breast Cancer

  2014cites this paper
• Dynamic Inversion Enables External Magnets To Concentrate Ferromagnetic Rods to a Central Target

  2014cites this paper
• ROYAUMEDUMAROC UNIVERSITESIDIMO HAMMEDBENABDELLA H FACULTEDEMEDECIN EETDEPHARMACIE FES

  2012cites this paper
• Magnetic nanoparticles as targeted delivery systems in oncology

  2011cites this paper
• Magnetic nanoparticles for gene and drug delivery

  2008cites this paper
• EVALUATION OF HUMAN PROLACTIN, ITS ANTAGONIST, AND ANTAGONIST-BASED FUSION PROTEINS AS CHEMOPREVENTATIVE AND THERAPEUTIC AGENTS

  2007cites this paper
• Endocrine treatment and prevention of breast and gynaecological cancers.

  2004cites this paper
• Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer

  2004cites this paper
• BRCA1 and Estrogen Signaling in Breast Cancer

  2003cites this paper
• Endocrine treatment and prevention of breast and gynaecological cancers

  2002cites this paper